Standard Contracts
2,500,000 Ordinary Shares Vascular Biogenics Ltd. EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • November 20th, 2017 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
Vascular Biogenics Ltd., an Israeli company (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named on Schedule I hereto for whom you are acting as the representative (the “Representative”) an aggregate of 2,500,000 shares (the “Shares”) of the Company’s ordinary shares, NIS 0.01 nominal value (the “Ordinary Shares”). The amount of the Shares to be so purchased by the several Underwriters are set forth opposite their names on Schedule I hereto.
